Personalis NeXT personal(r) data showcasing ultrasensitive MRD to be presented at ESMO 2026. Key Takeaway: Personalis, Inc. announced that it will present its NeXT Personal ctDNA test at the ESMO Congress 2026. The presentations will include two oral and two poster presentations, featuring a late-breaking oral presentation of data from the C-POST Phase 3 trial. The congress will take place from October 23-27 in Madrid, Spain. Market sentiment analysis. Positive factors. * Personalis will present at ESMO Congress 2026. * NeXT Personal data includes a late-breaking oral presentation. * The event showcases advancements in precision oncology. FREMONT, Calif.-(BUSINESS WIRE)-Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3 Frequently asked questions. What is the NeXT Personal ctDNA test? It is an ultrasensitive circulating tumor DNA test for precision oncology. When will the ESMO Congress 2026 take place? The congress will occur from October 23-27, 2026. What presentations will Personalis give at ESMO? Personalis will present two oral and two poster presentations. What is the C-POST Phase 3 trial? It is a trial related to the NeXT Personal ctDNA test data.

Tempus AI's $1.5B Personalis acquisition: why MRD is becoming a strategic battleground in cancer care. Tempus AI's planned $1.5 billion acquisition of Personalis is more than a conventional diagnostics deal. It signals a broader shift in oncology: blood-based cancer testing is moving from an emerging technology category to a strategic platform for diagnosis, treatment selection, recurrence detection, and long-term monitoring. The deal comes amid accelerating industry momentum: - Abbott recently completed its $21 billion acquisition of Exact Sciences - Guardant's blood-based colorectal cancer test gained UnitedHealthcare coverage - Freenome advanced its pivotal study for blood-based colorectal cancer screening The strategic logic behind the Personalis acquisition is clear. - Building an end-to-end oncology platform Personalis' molecular residual disease (MRD) test could strengthen Tempus' capabilities across the cancer care journey, from diagnosis to recurrence monitoring. - Combining complementary technologies Personalis brings a tumor-informed MRD assay, while Tempus has developed a tumor-naive approach. The combination provides broader coverage across evolving clinical use cases. - Acquiring at the right point in market maturity Tempus initially partnered with Personalis in 2023 rather than acquiring the company, allowing the MRD platform time to develop clinical traction and reimbursement coverage. That strategy now appears increasingly validated. Personalis has secured Medicare coverage in three indications, while preliminary second-quarter revenue reached $22.4 million. Test volumes also rose 33% sequentially to 10,384. The larger takeaway? In oncology diagnostics, the next competitive advantage may not come from a single test; but from owning the data, clinical evidence, reimbursement pathways, and longitudinal patient insights that connect testing to treatment decisions. Tempus' move suggests the future of cancer diagnostics will be increasingly integrated, data-driven, and centered on continuous monitoring - not one-time diagnosis. #TempusAI #Personalis #LiquidBiopsy #MRD #Oncology #CancerDiagnostics #MedTech #PrecisionMedicine #Diagnostics #HealthcareInnovation #MolecularDiagnostics #Biotechnology

Tempus to acquire Personalis for $1.5B, deepening bet on cancer diagnostics. Tempus AI has agreed to acquire Personalis, a Fremont, California-based maker of molecular residual disease (MRD) tests, for $1.5 billion, the companies announced Monday. Under the deal, Tempus will pay $16.25 per share for Personalis' outstanding stock - about a 6% premium to Friday's closing price - with the option to settle up to half the consideration in cash. The transaction is expected to close in late 2026 or early 2027, pending shareholder and regulatory approval. The acquisition builds on a commercial partnership the two companies formed in 2023 to co-market Personalis' MRD test, which screens for cancer recurrence. Tempus CEO Eric Lefkofsky told investors Monday that an outright purchase was considered back then too, but Tempus opted for the partnership route since Personalis still needed years of investment before its test could scale. Personalis has since secured Medicare coverage for three indications, with more expected. The combination pairs two different MRD approaches: Personalis' tumor-informed test, which draws on a patient's own tumor sample, and Tempus' tumor-naive offering. Lefkofsky said volume has "shifted pretty dramatically" toward tumor-informed testing in recent quarters, though Tempus still plans to invest in its tumor-naive line. On the numbers, Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 tests, up 33% from Q1. Tempus, meanwhile, sold roughly 9,000 Personalis tests in Q2, up from 5,500 in Q1. The deal lands amid a broader industry rush into blood-based cancer diagnostics: Abbott closed its $21 billion Exact Sciences acquisition in March, Guardant's Shield colon cancer blood test recently won UnitedHealth coverage, and Freenome just reported strong pivotal-study results for its own colorectal screening test.